Krsnaa Diagnostics Limited (KRSNAA) AI Stock Analysis

• Market Cap: ₹24.96B
• Dividend Yield: 0.38%
• Average Volume (3M): 12.28K
• Price to Earnings (P/E): 31.0
• Beta (1Y): 1.04
• Revenue Growth: 13.78%
• EPS Growth: 32.21%
• Country: IN
• Employees: 3,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 7.50
• Shares Outstanding: 32,438,670
• 10 Day Avg. Volume: 19,408
• 30 Day Avg. Volume: 12,281
• PEG Ratio: 0.98
• Price to Book (P/B): 2.95
• Price to Sales (P/S): 3.63
• P/FCF Ratio: -66.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹861.00 ▲(19.14% Upside)

Krsnaa Diagnostics Limited shows strong financial performance with robust revenue growth and a solid balance sheet, but faces challenges in cash flow management. Technical indicators suggest a lack of strong momentum, and the stock appears overvalued with a low dividend yield, impacting its attractiveness.

Krsnaa Diagnostics Limited Business Overview & Revenue Model

Company Description

Krsnaa Diagnostics Limited provides diagnostic services. The company offers a range of technology-enabled diagnostic services, such as radiology, pathology/clinical laboratory, and tele-radiology services to public and private hospitals, medical colleges, and community health centers. As of December 31, 2020, it operated 1,801 diagnostic centers in 13 states across India. The company was incorporated in 2010 and is based in Pune, India.

How the Company Makes Money

Krsnaa Diagnostics generates revenue primarily through its diagnostic services, including laboratory tests and imaging services. The company operates both a network of diagnostic centers and mobile diagnostic units, allowing it to reach a broad customer base. Key revenue streams include direct payments from patients for diagnostic tests, as well as contracts with hospitals and healthcare providers that refer patients for diagnostic services. Additionally, KRSNAA has established partnerships with government health initiatives and insurance companies, further enhancing its revenue opportunities by providing services through public health schemes and insurance reimbursements.

Krsnaa Diagnostics Limited Financial Statement Overview

Summary

Krsnaa Diagnostics Limited demonstrates strong revenue growth and profitability with a robust balance sheet. However, challenges in free cash flow generation present a potential risk, despite stable operating cash flows.

Income Statement

Krsnaa Diagnostics Limited shows strong revenue growth with a notable increase of 15.74% from 2024 to 2025. The company maintains a substantial gross profit margin of 76.38% for 2025, reflecting efficient cost management. However, while the net profit margin improved to 10.82%, there is room for enhancement in profitability metrics such as EBIT and EBITDA margins, which stand at 14.19% and 26.51% respectively. Overall, the income statement indicates a solid performance with positive growth trends.

Balance Sheet

The balance sheet of Krsnaa Diagnostics Limited is quite robust, with a healthy equity ratio of 68.87%, indicating a strong equity position relative to total assets. The debt-to-equity ratio at 0.23 suggests low financial leverage, which is a positive sign for financial stability. Additionally, the return on equity (ROE) is 8.79%, showing decent returns for shareholders. The balance sheet reflects sound financial management with a strong equity base and controlled leverage.

Cash Flow

The cash flow statement reveals challenges in free cash flow generation, with a negative free cash flow of -393 million in 2025, albeit an improvement from the previous year. The operating cash flow to net income ratio of 1.13 is solid, indicating good cash conversion efficiency. However, the company has faced difficulties in managing capital expenditures, which impacts free cash flow. Overall, while operating cash flows are stable, the negative free cash flow presents a potential risk area to address.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.40B	7.17B	6.20B	4.87B	4.55B	3.96B
Gross Profit	4.63B	5.48B	2.05B	4.13B	3.95B	3.13B
EBITDA	2.17B	2.16B	1.61B	1.42B	1.46B	3.59B
Net Income	802.09M	776.08M	568.37M	621.11M	683.88M	1.85B
Balance Sheet
Total Assets	0.00	12.82B	11.72B	9.10B	8.76B	6.05B
Cash, Cash Equivalents and Short-Term Investments	684.36M	684.36M	535.45M	1.09B	2.42B	1.53B
Total Debt	0.00	2.04B	1.60B	324.81M	409.92M	2.32B
Total Liabilities	-8.83B	3.99B	3.62B	1.71B	2.07B	3.73B
Stockholders Equity	8.83B	8.83B	8.10B	7.39B	6.84B	2.32B
Cash Flow
Free Cash Flow	0.00	-393.00M	-1.70B	-650.59M	-37.95M	357.18M
Operating Cash Flow	0.00	873.27M	243.45M	763.01M	1.28B	1.03B
Investing Cash Flow	0.00	-996.09M	-1.29B	-1.09B	-2.41B	-611.39M
Financing Cash Flow	0.00	137.53M	841.87M	-331.45M	1.76B	308.40M

Krsnaa Diagnostics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 722.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KRSNAA, the sentiment is Negative. The current price of 722.7 is below the 20-day moving average (MA) of 795.50, below the 50-day MA of 807.48, and below the 200-day MA of 771.00, indicating a bearish trend. The MACD of -15.71 indicates Positive momentum. The RSI at 30.80 is Neutral, neither overbought nor oversold. The STOCH value of 6.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KRSNAA.

Krsnaa Diagnostics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	68 Neutral	₹105.28B	70.08	―	0.20%	16.71%	13.92%
HCG	67 Neutral	₹107.77B	287.35	―	―	16.85%	-29.57%
LALPATHLAB	66 Neutral	₹264.07B	49.19	―	0.81%	10.80%	32.79%
MEDICAMEQ	65 Neutral	₹5.41B	53.96	―	0.25%	-9.90%	33.18%
KRSNAA	63 Neutral	₹24.96B	30.99	―	0.38%	13.78%	32.21%
METROPOLIS	61 Neutral	₹105.27B	68.82	―	―	15.41%	5.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Krsnaa Diagnostics Limited Corporate Events

Krsnaa Diagnostics Schedules Investor Meeting to Enhance Stakeholder Engagement

Krsnaa Diagnostics Limited has announced a scheduled meeting with investors and analysts on October 7, 2025, in Pune. The meeting will involve one-on-one interactions with high-net-worth individuals, focusing on publicly available information, ensuring no unpublished price-sensitive information is disclosed. This engagement reflects the company’s commitment to transparency and maintaining strong relationships with its stakeholders.

Krsnaa Diagnostics Releases Q1 2025 Financial Results

Krsnaa Diagnostics Limited announced the publication of its unaudited financial results for the quarter ending June 30, 2025, in prominent newspapers such as Financial Express and Loksatta. This disclosure is part of the company’s compliance with SEBI regulations, reflecting its commitment to transparency and providing stakeholders with timely financial information.

Krsnaa Diagnostics Releases Q1 FY2026 Financial Results

Krsnaa Diagnostics Limited has released an investor presentation detailing its unaudited financial results for the quarter ending June 30, 2025. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic positioning in the diagnostic services industry.